AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9492915 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (single 400 mg dose)
Number of subjects: 29
Study 7936563 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate (Timoptic)
Number of subjects: 45
Study 7936563 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobunolol (Betagan)
Number of subjects: 45
Study 3555385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 25 mg every two weeks
Number of subjects: 66
Study 3555385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 5 mg every two weeks
Number of subjects: 66
Study 3555385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate with dosage adjustment up to 10 mg
Number of subjects: 66
Study 3555385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 25 mg
Number of subjects: 66
Study 3555385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 5 mg
Number of subjects: 66
Study 30062951 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnum group (large femoral head)
Number of subjects: 119
Study 30062951 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (28 mm or 32 mm femoral head)
Number of subjects: 119
Study 28043438 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex Activation Therapy (BAT) plus medical therapy
Number of subjects: 140
Study 28043438 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 140
Study 25904747 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acyclovir treatment
Number of subjects: 301
Study 25904747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 23685637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (0.5 μg/kg/min)
Number of subjects: 41
Study 23685637 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 41
Study 20659400 — intervention group
Group type: EXPERIMENTAL
Intervention: Care plans (intervention group)
Number of subjects: 0
Study 20659400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no care plans)
Number of subjects: 0
Study 18825772 — intervention group
Group type: EXPERIMENTAL
Intervention: CBir1 stimulation
Number of subjects: 0
Study 16314619 — intervention group
Group type: EXPERIMENTAL
Intervention: Efaproxiral at 75 or 100 mg/kg
Number of subjects: 515
Study 16314619 — intervention group
Group type: COMPARATOR
Intervention: Control (no efaproxiral)
Number of subjects: 515
Study 14528576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing with essential oils
Number of subjects: 40
Study 14528576 — intervention group
Group type: COMPARATOR
Intervention: Nursing without essential oils
Number of subjects: 40
Study 10984077 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (graded intensity: 1.5, 2.0, and 2.5 W/kg, 6 min each)
Number of subjects: 20
Study 10984077 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (Actrapid MC Novo, 0.1 IU/kg, i.v.)
Number of subjects: 20
Study 10984077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (50 g and 100 g)
Number of subjects: 20
Study 10984077 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study 9010703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (112.5 to 675 mg, oral, every 12 h)
Number of subjects: 48
Study 9010703 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of pranlukast
Number of subjects: 48
Study 9010703 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening doses of pranlukast
Number of subjects: 48
Study 9010703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 48
Study 1476921 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) administered in fasting conditions
Number of subjects: 10
Study 1476921 — intervention group
Group type: COMPARATOR
Intervention: 8-methoxypsoralen (8-MOP) administered after food ingestion (low-fat or fat-rich breakfast)
Number of subjects: 10
Study 1476921 — intervention group
Group type: COMPARATOR
Intervention: 8-methoxypsoralen (8-MOP) ingested with > 50% smaller quantity of food than usual
Number of subjects: 10
Study 2870943 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin
Number of subjects: 0
Study 2870943 — intervention group
Group type: COMPARATOR
Intervention: Purified pork insulin
Number of subjects: 0
Study 31620931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy
Number of subjects: 40
Study 31620931 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 40
Study 30032191 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐122 (RA, 120 mg; PsA, 240 mg) subcutaneously every other week on background MTX
Number of subjects: 326
Study 27084589 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-glucidic nutrients (50g of Parmesan cheese, one boiled egg)
Number of subjects: 8
Study 24630262 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAI 50mg biweekly
Number of subjects: 160
Study 24630262 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAI 100mg biweekly
Number of subjects: 160
Study 24630262 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAI 50mg and 100mg
Number of subjects: 160
Study 24080920 — intervention group
Group type: EXPERIMENTAL
Intervention: larotaxel/cisplatin
Number of subjects: 337
Study 24080920 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/cisplatin
Number of subjects: 337
Study 19941058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) applied to dorsolateral prefrontal cortex (DLFPC)
Number of subjects: 13
Study 19941058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 13
Study 17765406 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 301
Study 17765406 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy
Number of subjects: 301
Study 16174272 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine mouthwash (10 ml, rinsed twice a day for 60 seconds)
Number of subjects: 21
Study 16174272 — intervention group
Group type: COMPARATOR
Intervention: 0.1% chlorhexidine (CHX) mouthwash (10 ml, rinsed twice a day for 60 seconds)
Number of subjects: 21
Study 16174272 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (10 ml, rinsed twice a day for 60 seconds)
Number of subjects: 21
Study 14604567 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-HIV-1(LAI)-nef vector vaccination
Number of subjects: 10
Study 10390940 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodrama groups
Number of subjects: 0
Study 10390940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8667921 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer maintenance chemotherapy (2 years)
Number of subjects: 12000
Study 8667921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and prednisone (VP) pulses during maintenance
Number of subjects: 12000
Study 8667921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive reinduction chemotherapy during maintenance
Number of subjects: 12000
Study 1512053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic, continuous, computerized on-line vectorcardiography for real-time monitoring of QRS-complex and ST-segment changes.
Number of subjects: 15
Study 6628528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 16
Study 6628528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxylated metabolites (4' and 5 mono and dihydroxy derivatives)
Number of subjects: 16
Study 30368495 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility exergaming (EXE)
Number of subjects: 74
Study 30368495 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling (CYC)
Number of subjects: 74
Study 30368495 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (CON)
Number of subjects: 74
Study 29265496 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication + proton pump inhibitor for 7 weeks
Number of subjects: 330
Study 29265496 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor for 8 weeks (non-eradication group)
Number of subjects: 330
Study 26857107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet1 - advice to reduce saturated fat intake
Number of subjects: 60
Study 26857107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet2 - Mediterranean Portfolio Diet with additional cholesterol-lowering foods (nuts, stanols, soya, oats, pulses)
Number of subjects: 60
Study 26857107 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score, 3-day food diaries and metabolomic biomarkers
Number of subjects: 60
Study 26857107 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Number of subjects: 60
Study 26857107 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 60
Study 26857107 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility assessment
Number of subjects: 60
Study 24337358 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological condition (N=176)
Number of subjects: 351
Study 24337358 — intervention group
Group type: COMPARATOR
Intervention: Control condition (N=175)
Number of subjects: 351
Study 22596166 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-biomarker disease activity (MBDA) score
Number of subjects: 20
Study 22596166 — intervention group
Group type: EXPERIMENTAL
Intervention: Study therapy (intensive or conventional methotrexate-based treatment)
Number of subjects: 20
Study 22596166 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDA score
Number of subjects: 20
Study 22596166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables
Number of subjects: 20
Study 20634720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg moxonidine (MOX) daily
Number of subjects: 23
Study 20634720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study 18225732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 301
Study 18225732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 301
Study 15897698 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 10 days
Number of subjects: 257
Study 15897698 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 10 days
Number of subjects: 257
Study 11916760 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII plus 200 mg alpha-tocopherol/d
Number of subjects: 98
Study 11916760 — intervention group
Group type: COMPARATOR
Intervention: CSII
Number of subjects: 98
Study 9840721 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (100mg/m2/1 h) administered immediately before and at the end (24 h) of MTX treatment
Number of subjects: 0
Study 9840721 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (100mg/m2/1 h) administered at 24 and 48 h after starting MTX infusion
Number of subjects: 0
Study 9840721 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (5g/m2/24 h)
Number of subjects: 0
Study 7500751 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (30 micrograms ethinyloestradiol)
Number of subjects: 285
Study 7500751 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive
Number of subjects: 285
Study 7500751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OCs with a third-generation progestagen
Number of subjects: 285
Study 2225484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg p.o. at -60 min)
Number of subjects: 6
Study 2225484 — intervention group
Group type: COMPARATOR
Intervention: GHRH (100 micrograms, i.v. at 0 min)
Number of subjects: 6
Study 495512 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5 mg oral dose of prazosin (Group A, no. = 7)
Number of subjects: 14
Study 495512 — intervention group
Group type: COMPARATOR
Intervention: Oral prazosin, 2 mg every 8 hours for 24 hours (Group B, no. = 7)
Number of subjects: 14
Study 30909863 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotypic analysis of swamp buffaloes
Number of subjects: 105
Study 30909863 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotypic analysis of crossbred buffaloes
Number of subjects: 105
Study 30909863 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotypic analysis of murrah buffaloes
Number of subjects: 105
Study 30909863 — intervention group
Group type: EXPERIMENTAL
Intervention: D-loop mitochondrial DNA analysis
Number of subjects: 105
Study 30909863 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic tree construction
Number of subjects: 105
Study 28340281 — intervention group
Group type: EXPERIMENTAL
Intervention: FND followed by rituximab
Number of subjects: 158
Study 28340281 — intervention group
Group type: COMPARATOR
Intervention: FND with concurrent rituximab
Number of subjects: 158
Study 25636947 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 DU of MK‐8237
Number of subjects: 124
Study 25636947 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 DU of MK‐8237
Number of subjects: 124
Study 25636947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22749917 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrations of IgA in patients with temporal lobe epilepsy (TLE)
Number of subjects: 856
Study 22749917 — intervention group
Group type: COMPARATOR
Intervention: Low concentrations of IgA
Number of subjects: 856
Study 22749917 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of topiramate
Number of subjects: 856
Study 22749917 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of lamotrigine, nitrazepam, oxcarbazepine, topiramate, and valproic acid
Number of subjects: 856
Study 22749917 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrations of IgG
Number of subjects: 856
Study 22749917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrations of IgG
Number of subjects: 856
Study 22029223 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of quetiapine fumarate 25 mg film-coated tablet
Number of subjects: 30
Study 22029223 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of quetiapine fumarate 25 mg film-coated tablet
Number of subjects: 30
Study 19346160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 5mg
Number of subjects: 742
Study 19346160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10mg
Number of subjects: 742
Study 19346160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15mg
Number of subjects: 742
Study 19346160 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10mg
Number of subjects: 742
Study 17917907 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise programme
Number of subjects: 27
Study 17917907 — intervention group
Group type: COMPARATOR
Intervention: Normal daily activities (Control)
Number of subjects: 27
Study 16293902 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise with 4 weeks interval (n = 9)
Number of subjects: 30
Study 16293902 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise with 8 weeks interval (n = 10)
Number of subjects: 30
Study 16293902 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise with 12 weeks interval (n = 11)
Number of subjects: 30
Study 12058781 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9887851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural home care programme
Number of subjects: 116
Study 9887851 — intervention group
Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 116
Study 9183985 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT task with secondary tone counting task and repeating sequences
Number of subjects: 0
Study 9183985 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT task with secondary tone counting task and non-repeating sequences
Number of subjects: 0
Study 9183985 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT task with varying inter-stimulus intervals
Number of subjects: 0
Study 9183985 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT task without secondary tone counting task and repeating sequences
Number of subjects: 0
Study 9183985 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT task without secondary tone counting task and non-repeating sequences
Number of subjects: 0
Study 2718829 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified balanced-placebo design
Number of subjects: 179
Study 2718829 — intervention group
Group type: COMPARATOR
Intervention: Standard balanced-placebo design
Number of subjects: 179
Study 1149490 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole (480 mg trimethoprim and 2,400 mg sulphamethoxazole daily)
Number of subjects: 116
Study 1149490 — intervention group
Group type: COMPARATOR
Intervention: tetracycline (2 g daily)
Number of subjects: 116
Study 29885826 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF score low-risk (≤1.45)
Number of subjects: 1901
Study 29885826 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF score intermediate-risk (>1.45 and ≤2.0)
Number of subjects: 1901
Study 29885826 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF score high-risk (>2.0)
Number of subjects: 1901
Study 29885826 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF score
Number of subjects: 1901
Study 28177187 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (T+C)
Number of subjects: 138
Study 28177187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (T+P)
Number of subjects: 138
Study 26298786 — intervention group
Group type: EXPERIMENTAL
Intervention: JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4)
Number of subjects: 33
Study 26298786 — intervention group
Group type: EXPERIMENTAL
Intervention: JZP-110
Number of subjects: 33
Study 26298786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23764991 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field digital retinal imaging (WFDRI)
Number of subjects: 58
Study 23764991 — intervention group
Group type: COMPARATOR
Intervention: Binocular indirect ophthalmoscopy (BIO)
Number of subjects: 58
Study 20508536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein recovery diet (1.4/0.7/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Number of subjects: 12
Study 20508536 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control condition (2.1/0.1/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Number of subjects: 12
Study 20508536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein condition
Number of subjects: 12
Study 20508536 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12
Study 18444947 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated autotransfusion system
Number of subjects: 24
Study 18444947 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-coated autotransfusion system
Number of subjects: 24
Study 16804556 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched oolong tea
Number of subjects: 12
Study 16804556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12906366 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg capsule in the evening)
Number of subjects: 12
Study 12906366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10784307 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 5 microg x ml(‐1)
Number of subjects: 28
Study 10784307 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 10 microg x ml(‐1)
Number of subjects: 28
Study 10784307 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (Control)
Number of subjects: 28
Study 9038439 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (single dose 2 h before surgery)
Number of subjects: 51
Study 9038439 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (every 12 h for 2 days before surgery)
Number of subjects: 51
Study 9038439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1889841 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin inhibitor Ro 42-5892 (0.3 mg/kg injected at 30 minutes, followed by infusion at 0.1 mg/kg/hr from 30 to 240 minutes)
Number of subjects: 6
Study 1889841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang II infusion (2 ng/kg/min from 0 to 60 minutes and 4 ng/kg/min from 60 to 120 minutes)
Number of subjects: 6
Study 1889841 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of Ang II and Ro 42-5892 (same doses as above)
Number of subjects: 6
Study 6133645 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocking drugs (specific drugs not mentioned)
Number of subjects: 0
Study 31712342 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based intervention for reducing the duration of invasive mechanical ventilation after an 8-week training period.
Number of subjects: 10000
Study 31712342 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline data collection) before the training period.
Number of subjects: 10000
Study 29417623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g daily)
Number of subjects: 58
Study 29417623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 26729895 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-lenalidomide (MPR)
Number of subjects: 662
Study 26729895 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide-prednisone-lenalidomide (CPR)
Number of subjects: 662
Study 26729895 — intervention group
Group type: COMPARATOR
Intervention: lenalidomide plus low-dose dexamethasone (Rd)
Number of subjects: 662
Study 26729895 — intervention group
Group type: COMPARATOR
Intervention: Triplet (MPR and CPR)
Number of subjects: 662
Study 26729895 — intervention group
Group type: COMPARATOR
Intervention: Doublet (Rd)
Number of subjects: 662
Study 26729895 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR
Number of subjects: 662
Study 26729895 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR
Number of subjects: 662